Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement.
作者信息
Köhler Thomas, Schwier Elke, Henzler Dietrich, Eickmeyer Claas
机构信息
Department of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, Germany.
Department of Anesthesiology, Surgical Intensive Care, Emergency and Pain Medicine, Ruhr University Bochum, Klinikum Herford, Herford, Germany.
出版信息
J Crit Care. 2021 Dec;66:187-188. doi: 10.1016/j.jcrc.2021.07.011. Epub 2021 Jul 27.
Abstract
摘要
相似文献
1
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement.使用CytoSorb进行辅助血液吸附是否会影响接受体外膜肺氧合（ECMO）治疗的COVID-19患者的生存率？一项批判性声明。
J Crit Care. 2021 Dec;66:187-188. doi: 10.1016/j.jcrc.2021.07.011. Epub 2021 Jul 27.
2
Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement.回复：使用CytoSorb®进行辅助血液吸附是否会影响接受体外膜肺氧合（ECMO）治疗的COVID-19患者的生存率？一项批判性声明。
J Crit Care. 2021 Dec;66:189-190. doi: 10.1016/j.jcrc.2021.07.013. Epub 2021 Jul 29.
3
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response.使用CytoSorb进行辅助血液吸附是否会影响接受体外膜肺氧合（ECMO）治疗的COVID-19患者的生存率？作者回应。
J Crit Care. 2021 Dec;66:31-32. doi: 10.1016/j.jcrc.2021.08.003. Epub 2021 Aug 18.
4
Hemoadsorption in critically ill patients with or without COVID-19: A word of caution.伴有或不伴有新型冠状病毒肺炎的危重症患者的血液吸附：一则警示
J Crit Care. 2021 Oct;65:140-141. doi: 10.1016/j.jcrc.2021.06.007. Epub 2021 Jun 12.
5
Impact of CytoSorb Hemoadsorption on Sedation Requirements in Patients With Severe COVID-19 on Venovenous Extracorporeal Membrane Oxygenation.CytoSorb 血液灌流对 COVID-19 合并 venovenous 体外膜肺氧合患者镇静需求的影响。
ASAIO J. 2021 Aug 1;67(8):856-861. doi: 10.1097/MAT.0000000000001513.
6
Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.回复苏帕迪等人。对以下内容的评论：在接受VV体外膜肺氧合的重症新型冠状病毒肺炎患者中进行体外血液吸附：新型冠状病毒肺炎细胞吸附疗法（CTC）注册研究。
Crit Care. 2023 Nov 2;27(1):421. doi: 10.1186/s13054-023-04678-1.
7
Adjuvant hemoadsorption therapy in patients with severe COVID-19 and related organ failure requiring CRRT or ECMO therapy: A case series.严重 COVID-19 合并相关器官衰竭患者接受 CRRT 或 ECMO 治疗时的辅助血液吸附治疗：一项病例系列研究。
Int J Artif Organs. 2021 Oct;44(10):694-702. doi: 10.1177/03913988211030517. Epub 2021 Jul 13.
8
Hemoadsorption treatment with CytoSorb in patients with extracorporeal life support therapy: A case series.细胞吸附剂（CytoSorb）用于体外生命支持治疗患者的血液吸附治疗：病例系列
Int J Artif Organs. 2020 Jun;43(6):422-429. doi: 10.1177/0391398819895287. Epub 2019 Dec 23.
9
Opportunities, controversies, and challenges of extracorporeal hemoadsorption with CytoSorb during ECMO.体外膜肺氧合（ECMO）期间使用CytoSorb进行体外血液吸附的机遇、争议与挑战。
Artif Organs. 2021 Oct;45(10):1240-1249. doi: 10.1111/aor.14025. Epub 2021 Aug 8.
10
Survival of Patients Treated With Extracorporeal Hemoadsorption and Extracorporeal Membrane Oxygenation: Results From a Nation-Wide Registry.接受体外血液吸附和体外膜肺氧合治疗患者的生存率：一项全国性登记研究结果
ASAIO J. 2023 Mar 1;69(3):339-343. doi: 10.1097/MAT.0000000000001788. Epub 2022 Jul 19.
引用本文的文献
1
Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms.体外吸附血液治疗在中毒性全身炎症中的不良后果：对可能机制的见解
Ann Intensive Care. 2022 Nov 12;12(1):105. doi: 10.1186/s13613-022-01078-6.
2
Use of CytoSorb© Hemoadsorption in Patients on Veno-Venous ECMO Support for Severe Acute Respiratory Distress Syndrome: A Systematic Review.细胞吸附柱（CytoSorb©）血液吸附在接受静脉-静脉体外膜肺氧合（Veno-Venous ECMO）支持的重症急性呼吸窘迫综合征患者中的应用：一项系统评价
J Clin Med. 2022 Oct 11;11(20):5990. doi: 10.3390/jcm11205990.
3
Immunomodulation by Hemoadsorption-Changes in Hepatic Biotransformation Capacity in Sepsis and Septic Shock: A Prospective Study.血液吸附的免疫调节作用——脓毒症和脓毒性休克时肝脏生物转化能力的变化：一项前瞻性研究
Biomedicines. 2022 Sep 20;10(10):2340. doi: 10.3390/biomedicines10102340.
4
Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorb-Basics, Indications and Perspectives-A Scoping Review.血液吸附治疗对细胞 Sorb-Basics 的宿主防御作用的调节：适应证和展望——范围综述。
Int J Mol Sci. 2021 Nov 26;22(23):12786. doi: 10.3390/ijms222312786.
5
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response.使用CytoSorb进行辅助血液吸附是否会影响接受体外膜肺氧合（ECMO）治疗的COVID-19患者的生存率？作者回应。
J Crit Care. 2021 Dec;66:31-32. doi: 10.1016/j.jcrc.2021.08.003. Epub 2021 Aug 18.
本文引用的文献
1
Hemoadsorption in critically ill patients with or without COVID-19: A word of caution.伴有或不伴有新型冠状病毒肺炎的危重症患者的血液吸附：一则警示
J Crit Care. 2021 Oct;65:140-141. doi: 10.1016/j.jcrc.2021.06.007. Epub 2021 Jun 12.
2
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.严重新型冠状病毒肺炎需体外膜肺氧合治疗患者的细胞因子吸附（CYCOV）：一项单中心、开放标签、随机对照试验
Lancet Respir Med. 2021 Jul;9(7):755-762. doi: 10.1016/S2213-2600(21)00177-6. Epub 2021 May 14.
3
High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: A retrospective cohort study.大剂量细胞吸附柱血液吸附与感染性休克患者生存率提高相关：一项回顾性队列研究。
J Crit Care. 2021 Aug;64:184-192. doi: 10.1016/j.jcrc.2021.04.011. Epub 2021 Apr 20.
4
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
5
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
6
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.COVID-19 患者的体外膜肺氧合支持：体外生命支持组织登记处的国际队列研究。
Lancet. 2020 Oct 10;396(10257):1071-1078. doi: 10.1016/S0140-6736(20)32008-0. Epub 2020 Sep 25.
Zotero 插件